Search
Exact Sciences Corp
EXASAdd to Watchlist
104.910USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
20.03BMarket Cap
LossP/E TTM
More Details of Exact Sciences Corp Company
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Exact Sciences Corp Info
Ticker SymbolEXAS
Company nameExact Sciences Corp
IPO dateJan 30, 2001
CEOConroy (Kevin T)
Number of employees6900
Security typeOrdinary Share
Fiscal year-endJan 30
Address5505 Endeavor Lane
CityMADISON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code53719
Phone16082845700
Websitehttps://www.exactsciences.com/
Ticker SymbolEXAS
IPO dateJan 30, 2001
CEOConroy (Kevin T)
Company Executives of Exact Sciences Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Commercial
1.52B
46.79%
Medicare Parts B & C
1.15B
35.46%
Other
352.22M
10.85%
International
223.84M
6.89%
By RegionUSD
Name
Revenue
Proportion
United States (Country)
3.02B
93.11%
Outside of united states
223.84M
6.89%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Commercial
1.52B
46.79%
Medicare Parts B & C
1.15B
35.46%
Other
352.22M
10.85%
International
223.84M
6.89%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HBK Investments, L.P.
4.01%
BlackRock Institutional Trust Company, N.A.
3.81%
Pentwater Capital Management LP
3.80%
BlackRock Financial Management, Inc.
2.62%
State Street Investment Management (US)
2.19%
Other
83.58%
Shareholders
Shareholders
Proportion
HBK Investments, L.P.
4.01%
BlackRock Institutional Trust Company, N.A.
3.81%
Pentwater Capital Management LP
3.80%
BlackRock Financial Management, Inc.
2.62%
State Street Investment Management (US)
2.19%
Other
83.58%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.83%
Investment Advisor/Hedge Fund
21.00%
Investment Advisor
13.69%
Research Firm
3.11%
Sovereign Wealth Fund
1.80%
Private Equity
0.82%
Pension Fund
0.79%
Bank and Trust
0.60%
Individual Investor
0.21%
Other
32.16%
Institutional Shareholding
Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1452
147.12M
77.07%
-48.70M
2025Q4
1286
180.92M
105.49%
--
2025Q3
1352
180.95M
106.13%
-112.86K
2025Q2
1416
180.92M
107.16%
-6.42M
2025Q1
1400
186.11M
105.23%
-12.34M
2024Q4
1391
186.68M
107.44%
-1.15M
2024Q3
1351
188.95M
104.99%
+4.63M
2024Q2
1335
183.23M
95.81%
+15.73M
2024Q1
1330
166.64M
95.05%
-5.91M
2023Q4
1339
163.38M
96.52%
-2.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HBK Investments, L.P.
7.65M
4.01%
+7.65M
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.28M
3.81%
+121.88K
+1.70%
Dec 31, 2025
Pentwater Capital Management LP
7.25M
3.8%
+7.25M
--
Dec 31, 2025
BlackRock Financial Management, Inc.
5.00M
2.62%
+3.56M
+247.46%
Dec 31, 2025
State Street Investment Management (US)
4.18M
2.19%
-1.01M
-19.48%
Dec 31, 2025
Balyasny Asset Management LP
4.09M
2.14%
+3.24M
+382.56%
Dec 31, 2025
Millennium Management LLC
3.44M
1.8%
+1.22M
+55.20%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
3.43M
1.8%
+2.52M
+276.89%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.33M
1.75%
+19.75K
+0.60%
Dec 31, 2025
MFS Investment Management
2.72M
1.42%
-1.10M
-28.83%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust Nasdaq Lux Digi Health Solutions ETF
4.48%
Invesco Biotechnology & Genome ETF
3.72%
First Trust NYSE Arca Biotechnology Index Fund
3.72%
Alger Mid Cap 40 ETF
3.61%
Clough Select Equity ETF
3.13%
Clough Hedged Equity ETF
2.78%
iShares Health Innovation Active ETF
2.72%
State Street SPDR S&P Biotech ETF
2.32%
First Trust Indxx Medical Devices ETF
2.22%
ROBO Global Healthcare Technology & Innovation ETF
2.03%
View more
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.48%
Invesco Biotechnology & Genome ETF
Proportion3.72%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.72%
Alger Mid Cap 40 ETF
Proportion3.61%
Clough Select Equity ETF
Proportion3.13%
Clough Hedged Equity ETF
Proportion2.78%
iShares Health Innovation Active ETF
Proportion2.72%
State Street SPDR S&P Biotech ETF
Proportion2.32%
First Trust Indxx Medical Devices ETF
Proportion2.22%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
